



## **Aptinyx Presents NYX-2925 Preclinical Data in Chemotherapy-induced Neuropathic Pain at the American Pain Society Annual Scientific Meeting**

March 6, 2018

**Evanston, Ill., March 6, 2018** – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced their presentation at the American Pain Society’s Annual Scientific Meeting, March 4-6, 2018 in Anaheim, CA. The presentation features results from preclinical studies that further demonstrate efficacy and tolerability of Aptinyx’s lead product candidate, NYX-2925, a novel modulator of the N-methyl-D-aspartate (NMDA) receptor, in neuropathic pain.

“We have studied NYX-2925 across an array of preclinical models of neuropathic pain and have consistently seen favorable tolerability, rapid-acting effects, and durable responses achieved by modulation of the NMDA receptor,” said Joseph Moskal, Ph.D., chief scientific officer of Aptinyx. “The growing body of preclinical evidence of NYX-2925’s activities bolsters our confidence in our two ongoing clinical studies in neuropathic pain.”

### **Presentation Details**

#### **NYX-2925, a NMDA receptor modulator, shows efficacy in the rat taxol chemotherapy-induced peripheral neuropathy model (Poster #115)**

**Presenter:** Nayereh Ghoreishi-Haack, Aptinyx

**Poster Session:** Monday and Tuesday, March 5-6, 2018

**Presentation Time:** Author-attended poster session Monday, March 5th from 12:15 p.m. – 1:15 p.m. PST

**Abstract Available:** [The Journal of Pain](#), Vol. 19, Issue 3, S5-S6, March 2018.

**Summary:** A single oral dose of NYX-2925 produces significant analgesia up to 24 hours post-dose compared to three daily administrations and only one-hour post-dose efficacy of gabapentin in a model of chemotherapy-induced peripheral neuropathy. NYX-2925 also demonstrated tolerability in both taxol-injected and naive rats.

Discovered by Aptinyx scientists leveraging the company’s proprietary small-molecule chemistry platform, NYX-2925 is an oral, small-molecule NMDA receptor modulator. NYX-2925 binds to a novel site on the NMDA receptor and enhances synaptic plasticity to restore normal neural cell function. This mechanism is distinct from those of any other therapies, emerging or marketed, for neuropathic pain.

Aptinyx is currently conducting a Phase 2 [study](#) of NYX-2925 in patients with neuropathic pain associated with diabetic peripheral neuropathy (DPN), as well as an exploratory [study](#) in patients with fibromyalgia. The U.S. Food and Drug Administration has granted Fast Track designation to Aptinyx’s development of NYX-2925 for the treatment of neuropathic pain associated with DPN.

### **About Aptinyx**

Aptinyx Inc. is a clinical-stage biopharmaceutical company discovering and developing transformative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. Drugs that modulate NMDA receptors in this distinct way have both robust efficacy and exceptionally favorable safety. The company’s lead drug candidate, NYX-2925, is in Phase 2 clinical development as a therapy for neuropathic pain and its second drug candidate, NYX-783, is in Phase 1 clinical development for the treatment of post-traumatic stress disorder (PTSD). Both programs have received Fast Track designation by the FDA. Aptinyx is also advancing additional compounds from its proprietary chemistry platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit [www.aptinyx.com](http://www.aptinyx.com).

### **Company Contact:**

Nick Smith

Director, Corporate Development

Aptinyx Inc.

[corporate@aptinyx.com](mailto:corporate@aptinyx.com)

847-871-0377

### **Media Contact:**

Jordann Phillips

Canale Communications

[jordann@canalecomm.com](mailto:jordann@canalecomm.com)

619-849-6009